How menopause and HIV together affect cardiovascular disease risk in women.
The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women
This study will see if menopause combined with HIV raises heart disease risk in women with HIV by examining risk factors, inflammation, body composition, and whole-body MRI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT07284082 on ClinicalTrials.gov |
What this trial studies
Investigators will combine previously collected clinical and laboratory data with new whole-body MRI scans to study cardiovascular risk factors in 90 women with HIV across different menopausal stages at the UCSF MWCCS site. The study examines insulin resistance, blood pressure, blood lipids, carotid atherosclerosis, systemic inflammation, and how body fat distribution may modify these relationships. Eligible participants must be non-pregnant, on antiretroviral therapy, and virally suppressed, while women with prior hysterectomy/oophorectomy or receiving treatment for active cancer or tuberculosis are excluded. This observational approach aims to identify mechanisms by which menopause and HIV may jointly accelerate cardiovascular disease in women.
Who should consider this trial
Good fit: Ideal participants are non-pregnant women living with HIV who are on antiretroviral therapy, virally suppressed (HIV RNA <200 copies/mL), enrolled at the UCSF MWCCS site, and willing to undergo whole-body MRI, with roughly 30 women planned per menopausal stage.
Not a fit: Women who are not virally suppressed, not on antiretroviral therapy, have had hysterectomy or oophorectomy, are receiving treatment for active cancer or tuberculosis, or who cannot travel to UCSF are not eligible and therefore would not receive benefit from this specific study.
Why it matters
Potential benefit: If successful, the findings could help clinicians target prevention and monitoring strategies to reduce heart disease risk in menopausal women living with HIV.
How similar studies have performed: Prior research has linked HIV and menopause separately to increased cardiovascular risk, but few studies have combined both exposures with whole-body MRI and inflammation measures, so this approach is only partially tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site. Exclusion Criteria: * Women who are not virally suppressed (HIV RNA \>200 copies/mL) * Women who are not on antiretroviral therapy * Women who have a history of hysterectomy or oophorectomy * Women who are receiving treatment for active cancer or tuberculosis
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Rebecca Abelman, MD — University of California, San Francisco
- Study coordinator: Rebecca A Abelman, MD
- Email: rebecca.abelman@ucsf.edu
- Phone: 415-221-4810
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.